By applying this screening approach to our pediatric ALL cohort we identified, besides the most prominent BTG1 deletions, additional deletions in a substantial fraction (18%) of BCP-ALL cases at the subclonal level. Here, BTG1 is linked to acute lymphoblastic leukemia.